ENVERIC BIOSCIENCES, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ENVERIC BIOSCIENCES, INC. (ENVB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $125.11 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- ENVERIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $125.11K, a 39.34% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $88.67K, a 54.26% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $186.98K, a 49.41% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $206.26K, a 44.20% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $827.32K, a 47.05% decline from fiscal 2024.
- ENVERIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.56M, a 27.34% decline from fiscal 2023.
- ENVERIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.15M, a 17.95% decline from fiscal 2022.
- ENVERIC BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.62M, a 79.20% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $125.11K 10-Q · filed 2026-08-14 | $213.79K derived: sum of 2 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $88.67K 10-Q · filed 2026-08-14 | ||||
| 2025-12-31 | $827.32K 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | $186.98K 10-Q · filed 2025-11-14 | $393.24K derived: sum of 2 quarters · filed 2026-08-14 | $587.09K derived: sum of 3 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $206.26K 10-Q · filed 2026-08-14 | $400.11K derived: sum of 2 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $193.85K 10-Q · filed 2026-08-14 | ||||
| 2024-12-31 | $1.56M 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | $369.61K 10-Q · filed 2025-11-14 | $739.23K derived: sum of 2 quarters · filed 2025-11-14 | $1.09M derived: sum of 3 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $369.61K 10-Q · filed 2025-11-14 | $721.10K derived: sum of 2 quarters · filed 2025-11-14 | |||
| 2024-03-31 | $351.49K 10-Q · filed 2025-11-14 | ||||
| 2023-12-31 | $2.15M 10-K · filed 2025-03-28 | ||||
| 2023-09-30 | $372.86K 10-Q · filed 2024-11-14 | $1.25M derived: sum of 2 quarters · filed 2024-11-14 | $1.79M derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $879.74K 10-Q · filed 2024-11-14 | $1.41M derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $532.84K 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $2.62M 10-K · filed 2024-03-26 | ||||
| 2022-09-30 | $645.14K 10-Q · filed 2023-11-13 | $1.32M derived: sum of 2 quarters · filed 2023-11-13 | $2.09M derived: sum of 3 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $677.54K 10-Q · filed 2023-11-13 | $1.45M derived: sum of 2 quarters · filed 2023-11-13 | |||
| 2022-03-31 | $768.62K 10-Q · filed 2023-11-13 | ||||
| 2021-12-31 | $12.60M 10-K/A · filed 2023-06-09 | ||||
| 2021-09-30 | $486.99K 10-Q · filed 2022-11-14 | $1.24M derived: sum of 2 quarters · filed 2022-11-14 | $4.83M derived: sum of 3 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $750.93K 10-Q · filed 2022-11-14 | $4.34M derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2021-03-31 | $3.59M 10-Q · filed 2022-11-14 | ||||
| 2020-03-31 | $19.81K 10-Q · filed 2020-05-15 | -$11.29K derived: sum of 2 quarters · filed 2021-04-01 | $65.22K derived: sum of 3 quarters · filed 2021-04-01 | $278.02K derived: sum of 4 quarters · filed 2021-04-01 | |
| 2019-12-31 | -$31.11K derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-01 | $45.41K derived: sum of 2 quarters · filed 2021-04-01 | $258.21K derived: sum of 3 quarters · filed 2021-04-01 | $535.59K 10-K · filed 2021-04-01 | $586.50K 10-K · filed 2020-03-25 |
| 2019-09-30 | $76.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $289.31K derived: sum of 2 quarters · filed 2019-11-08 | $566.69K 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | $212.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $490.18K 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $277.38K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |